Next Generation of Cancer Immunotherapy

Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

The Company has assembled a world class management team with extensive expertise and a successful track record in drug development and commercialization of cancer immunotherapies.

Confronting a Global Issue

The World Health Organization estimates that 2.3 million woman are at risk for HPV-associated cervical cancer globally. Developed with cutting edge technology, ADXS-HPV aims to lower that number.
Learn More

A Better Way to Fight Cancer

Advaxis is pioneering a novel platform technology using bio-engineered bacteria to secrete protein(s) designed to redirect the powerful immune response all human beings have to HPV-associated cancer. Much like a Trojan Horse... but on a smaller scale.
Learn More

Advaxis, Inc. (ADXS)

Advaxis News

Latest News

Japan Patent Office Issues Advaxis a Notice of All...

PRINCETON, N.J., April 14, 2014 (GLOBE NEWSWIRE) ... Read More

About Advaxis

About Advaxis

The Next Generation of Cancer Immunotherapy is Here

Advaxis is a clinical stage biotechnology company.

Learn more

Clinical Pipeline

Clinical Pipeline

Clinical trials for the treatment of HPV-associated cancers

ADXS-HPV, Advaxis’ lead drug candidate is in clinical trials for HPV-associated cancers.

Learn More